Crenolanib for treating FLT3 mutated proliferative disorders associated mutations

A method for treating a human patient suffering from acute myelogenous leukemia (AML) comprising:

• obtaining a biological sample from the human patient;
• determining from the sample that the human patient has AML with a deregulated FLT3 receptor or a constitutively active FLT3 receptor;
• determining that the AML has one or more driver mutations in a DNMT3A gene;
• and
• administering to the human patient in need of such treatment for AML determined to have both the deregulated FLT3 receptor or a constitutively active FLT3 receptor and the one or more driver mutations in the DNMT3 A gene a therapeutically effective amount of crenolanib or a salt thereof, thereby treating the AML.

A method for specifically inhibiting a deregulated or constitutively active FLT3 receptor tyrosine kinase, comprising:

• obtaining a sample from a human patient having acute myelogenous leukemia (AML);
• determining that the AML has a FLT3 receptor tyrosine kinase that is deregulated or constitutively active and one or more driver mutations in a DNMT3A gene by performing or having performed genetic testing on the sample from the patient;
• wherein the AML with both the deregulated or constitutively active FLT3 receptor tyrosine kinase and the one or more driver mutations in a DNMT3A gene cause a poor prognosis from the presence of both the deregulated FLT3 receptor tyrosine kinase and the driver mutation in DNMT3A;
• and
• administering to the human patient in need of such treatment for AML determined to have both the deregulated or constitutively active FLT3 receptor tyrosine kinase and the one or more driver mutations in a DNMT3 A gene a therapeutically effective amount of crenolanib or a salt thereof, sufficient to reduce or eliminate the AML.